Trial watch: An all-oral and interferon-free future for HCV therapy?

@article{2011TrialWA,
  title={Trial watch: An all-oral and interferon-free future for HCV therapy?},
  author={},
  journal={Nature Reviews Drug Discovery},
  year={2011},
  volume={10},
  pages={891-891}
}
  • Published 2011
  • Medicine
  • Nature Reviews Drug Discovery
hepatitis C virus (HCV) infection involves treatment with ribavirin and pegylated interferon (PEG-IFN). This stimulates the immune system rather than targeting the virus directly, and is associated with severe side effects. Earlier this year, the first two direct-acting antiviral agents (DAAs), the protease inhibitors telaprevir (Incivek; Vertex/Johnson & Johnson) and boceprevir (Victrelis; Merck), were approved by the US Food and Drug Administration; however, these still have to be… Expand
1 Citations